These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2611821)

  • 21. Postantibiotic effects of amikacin and ofloxacin on Mycobacterium fortuitum.
    Tsui SY; Yew WW; Li MS; Chan CY; Cheng AF
    Antimicrob Agents Chemother; 1993 May; 37(5):1001-3. PubMed ID: 8517688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disk diffusion testing with polymyxin and amikacin for differentiation of Mycobacterium fortuitum and Mycobacterium chelonei.
    Wallace RJ; Swenson JM; Silcox VA; Good RC
    J Clin Microbiol; 1982 Dec; 16(6):1003-6. PubMed ID: 6298271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro antimycobacterial activity of a new quinolone, T-3761].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1995 Feb; 70(2):97-101. PubMed ID: 7699982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial activity of antibiotics in combination with natural flavonoids against clinical extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae.
    Lin RD; Chin YP; Lee MH
    Phytother Res; 2005 Jul; 19(7):612-7. PubMed ID: 16161024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Susceptibility to antimicrobial agents of rapidly growing mycobacteria].
    Ruiz-Aragón J; García-Agudo L; Flores S; Rodríguez MJ; Marín P; García-Martos P
    Rev Esp Quimioter; 2007 Dec; 20(4):429-32. PubMed ID: 18563216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Evidence is based on plasmid analysis, mutational frequencies, and aminoglycoside-modifying enzyme assays.
    Wallace RJ; Hull SI; Bobey DG; Price KE; Swenson JM; Steele LC; Christensen L
    Am Rev Respir Dis; 1985 Aug; 132(2):409-16. PubMed ID: 4026065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae.
    Dhople AM; Ibanez MA; Gardner GD
    Arzneimittelforschung; 1993 Mar; 43(3):384-6. PubMed ID: 8387790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [In vitro sensitivity of Mycobacterium chelonae strains to various antimicrobial agents].
    Hernández García AM; Arias A; Felipe A; Alvarez R; Sierra A
    Microbiologia; 1995 Dec; 11(4):485-90. PubMed ID: 8588844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study of cefoperazone and amikacin.
    Whang CW; Chung ES; Chang ST
    Clin Ther; 1984; 7(1):40-8. PubMed ID: 6518463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Sensitivity of 7 mycobacterial species to new quinolones].
    Gevaudan MJ; Mallet MN; Gulian C; Terriou P; Lagier P; de Micco P
    Pathol Biol (Paris); 1988 May; 36(5):477-81. PubMed ID: 3136429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In vitro antimycobacterial activity of a new quinolone, NM394].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1993 Aug; 68(8):517-20. PubMed ID: 8397311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.
    Rastogi N; Goh KS; Bryskier A
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1433-8. PubMed ID: 8092850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.
    Bin C; Hui W; Renyuan Z; Yongzhong N; Xiuli X; Yingchun X; Yuanjue Z; Minjun C
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):351-7. PubMed ID: 16934430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China.
    Pang H; Li G; Zhao X; Liu H; Wan K; Yu P
    Biomed Res Int; 2015; 2015():419392. PubMed ID: 26351633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria.
    Tomioka H; Sato K; Saito H
    Tubercle; 1991 Sep; 72(3):176-80. PubMed ID: 1771676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial susceptibility testing of Mycobacterium fortuitum complex.
    Welch DF; Kelly MT
    Antimicrob Agents Chemother; 1979 Jun; 15(6):754-7. PubMed ID: 475359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Etest for rapid susceptibility testing of Mycobacterium chelonae and M. fortuitum.
    Hoffner SE; Klintz L; Olsson-Liljequist B; Bolmström A
    J Clin Microbiol; 1994 Aug; 32(8):1846-9. PubMed ID: 7989530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of trimethoprim and sulfamethoxazole against the nontuberculous mycobacteria.
    Wallace RJ; Wiss K; Bushby MB; Hollowell DC
    Rev Infect Dis; 1982; 4(2):326-31. PubMed ID: 7111959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ofloxacin combined with Lactobacillus casei against Mycobacterium fortuitum infection induced in mice.
    Tomioka H; Sato K; Saito H
    Antimicrob Agents Chemother; 1990 Apr; 34(4):632-6. PubMed ID: 2344170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of the in vitro susceptibility of 220 Mycobacterium fortuitum isolates to ten antimicrobial agents.
    Hernández AM; Arias A; Felipe A; Alvarez R; Sierra A
    J Chemother; 1995 Dec; 7(6):503-8. PubMed ID: 8667033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.